Daily close, T-120 (2/13/25) through T+5. Run-up high $35.19 on 7/16/25, low $18.32 on 4/14/25 (T-120 to T-1). FDA decision 7/31/25. Historical price action, not a forecast.
Positioning before the decision
On Jul 17, 2025, 14 days before the decision date, at-the-money options priced a move of ±23.0% through Aug 15, 2025 (the first listed expiry after the decision; ATM implied volatility 102%). The stock closed -3.2% at the first close across the decision and -1.9% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Was VIZZ (aceclidine ophthalmic solution) approved by the FDA?
Yes. The FDA approved the application for VIZZ (aceclidine ophthalmic solution) on July 31, 2025. The primary source is linked on this page.
What was VIZZ (aceclidine ophthalmic solution) under FDA review for?
The application covered Presbyopia. The FDA approved the application on July 31, 2025.
How did LENZ stock react to the FDA decision?
On the decision day LENZ moved -3.2%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.